Literature DB >> 11817305

Determination of LSD and its metabolites in human biological fluids by high-performance liquid chromatography with electrospray tandem mass spectrometry.

J Canezin1, A Cailleux, A Turcant, A Le Bouil, P Harry, P Allain.   

Abstract

A liquid chromatographic procedure with electrospray ionization tandem mass spectrometric detection has been developed and validated for LSD and iso-LSD determination. A one-step liquid-liquid extraction on 1 ml blood or urine was used. The lower limit for quantitative determination was 0.02 microg/l for LSD and iso-LSD. The analytical procedure has been applied in two positive cases (case 1: LSD=0.31 microg/l, iso-LSD=0.27 microg/l in plasma and LSD=1.30 microg/l, iso-LSD=0.82 microg/l in urine; case 2: LSD=0.24 microg/l, iso-LSD=0.6 microg/l in urine). LSD metabolism was investigated using MS-MS neutral loss monitoring for the screening of potential metabolites. The main metabolite was 2-oxo-3-hydroxy-LSD (O-H-LSD) present in urine at the concentrations of 2.5 microg/l and 6.6 microg/l, respectively, for case 1 and 2, and was not present in plasma. Nor-LSD was also found in urine at 0.15 and 0.01 microg/l levels. Nor-iso-LSD, lysergic acid ethylamide (LAE), trioxylated-LSD, lysergic acid ethyl-2-hydroxyethylamide (LEO) and 13 and 14-hydroxy-LSD and their glucuronide conjugates were detected in urine using specific MS-MS transitions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11817305     DOI: 10.1016/s0378-4347(01)00386-3

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  8 in total

1.  Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects.

Authors:  Friederike Holze; Urs Duthaler; Patrick Vizeli; Felix Müller; Stefan Borgwardt; Matthias E Liechti
Journal:  Br J Clin Pharmacol       Date:  2019-04-29       Impact factor: 4.335

2.  Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS.

Authors:  Rafaela Martin; Jennifer Schürenkamp; Angela Gasse; Heidi Pfeiffer; Helga Köhler
Journal:  Int J Legal Med       Date:  2012-11-27       Impact factor: 2.686

3.  Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial.

Authors:  Patrick C Dolder; Matthias E Liechti; Katharina M Rentsch
Journal:  J Clin Lab Anal       Date:  2017-05-26       Impact factor: 2.352

Review 4.  Analysis of Ergot Alkaloids.

Authors:  Colin Crews
Journal:  Toxins (Basel)       Date:  2015-06-03       Impact factor: 4.546

5.  Recent Advances in Mass Spectrometry for the Identification of Neuro-chemicals and their Metabolites in Biofluids.

Authors:  Suresh Kumar Kailasa; Hui-Fen Wu
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

6.  Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.

Authors:  Patrick C Dolder; Yasmin Schmid; Manuel Haschke; Katharina M Rentsch; Matthias E Liechti
Journal:  Int J Neuropsychopharmacol       Date:  2015-06-24       Impact factor: 5.176

7.  LC-ESI-MS/MS on an ion trap for the determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine and vitreous humor.

Authors:  Donata Favretto; Giampietro Frison; Sergio Maietti; Santo Davide Ferrara
Journal:  Int J Legal Med       Date:  2006-02-23       Impact factor: 2.791

8.  Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).

Authors:  Adam L Halberstadt; Muhammad Chatha; Adam K Klein; John D McCorvy; Markus R Meyer; Lea Wagmann; Alexander Stratford; Simon D Brandt
Journal:  Neuropharmacology       Date:  2019-11-19       Impact factor: 5.273

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.